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Abstract: Statins are effective lipid lowering agents traditionally used for the primary and secondary prevention of car-
diovascular disease. Statins also exert a range of pleiotropic effects that make them attractive candidates for use in a wide 
range of disorders, in particular inflammatory and immune mediated conditions. However, the exploitation of such plei-
otropic effects has been greatly hindered by poor bioavailability and adverse effects on muscles and the liver at higher 
doses. Nanotechnology is often suggested as the solution to this problem, as it enables an increased bioavailability of stat-
ins. Moreover, colloidal carriers can offer targeted drug delivery approaches that enable localised biological effects of 
statins, further reducing their potential for unwanted toxicity and adverse effects. This article reviews the available evi-
dences for the increased potential of statin therapy when administered in nano-formulations such as nanocrystals, 
nanoparticles, liposomes, micelles and various nano-enabled devices. 
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1. INTRODUCTION 
1.1. Statins as Cholesterol Lowering Agents 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors or statins are arguably one of the 
biggest advances in cardiovascular care of the 20
th
 century. 
Statins reduce cholesterol serum levels by reversibly inhibit-
ing HMG-CoA reductase, an enzyme catalysing a rate-
limiting step in cholesterol biosynthesis [1]. Since statins 
were approved in 1987, their use has steadily increased 
worldwide, being the largest drug cost to the Australian 
Pharmaceutical Benefits Scheme (PBS) starting from 1997. 
Since 2001 atorvastatin has maintained the standing of pre-
scription most dispensed each year in Australia [2]. 
The wide acceptance of statins as lipid lowering agents is 
justified after many years of thorough investigation into their 
effects. In 1994 the first significant cholesterol lowering 
trial, i.e., the Scandinavian Simvastatin Survival Study (4S 
trial), showed that simvastatin decreased blood levels of total 
cholesterol by 25%, LDL-cholesterol by 35% and raised 
HDL-cholesterol by 8% and more importantly, this trial 
showed simvastatin-dependent decreased mortality of pa-
tients, which sparked global interest [3]. Later studies 
showed the benefits of statins for primary prevention of car-
diovascular disease [4-6]. Collectively, these extensive clini-
cal trials have proven that long-term therapy with statins (for 
at least one year) reduces the risk of heart attack, stroke and 
all-cause mortality in patients with and without established 
coronary heart disease [7]. 
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Currently available statins include atorvastatin, fluvas-
tatin, lovastatin, pravastatin, pitavastatin, rosuvastatin and 
simvastatin. From a chemical standpoint, statins have differ-
ent structures, some being more lipophilic than others  
(Fig. 1) [8]. 
These chemical differences among statins impact signifi-
cantly on their pharmacokinetic profiles (Table 1) [9-11]. 
Atorvastatin, fluvastatin, lovastatin, pitavastatin and simvas-
tatin are lipophilic in nature, thus easily diffuse across en-
terocytes cell membranes and are active not only in the liver, 
but also in non-hepatic tissues. Rosuvastatin and pravastatin 
have a more hydrophilic character, which decreases their 
permeability across cell membranes, but are actively trans-
ported into the hepatocytes by organic anion transporters 
(OATP). Apart from pravastatin, which is transformed en-
zymatically in the liver cytosol, all statins undergo extensive 
metabolism by the cytochrome P450 (CYP) isoenzyme sys-
tems expressed in liver microsomes and in the gut wall [9]. 
Lipophilic statins generally exhibit poor bioavailability vary-
ing from 5% (simvastatin) to 24% (fluvastatin) upon oral 
administration [10]. The low bioavailability of these statins 
is due to a combination of poor aqueous solubility, low dis-
solution rate and extensive first pass metabolism. The low 
systemic bioavailability of statins has previously been indi-
cated as a desirable feature, since statins exert their main 
pharmacological effect by lowering cholesterol synthesis in 
hepatic cells. However, statins are increasingly being inves-
tigated for other pharmacological effects in which higher 
systemic bioavailability is desired. 
1.2. Beyond the Cholesterol Lowering Effect of Statins 
Along with their lipid lowering effects, statins have been 
related to a range of other therapeutic outcomes or plei-
otropic effects. These pleiotropic effects were first evidenced
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Fig. (1). Molecular structures of hydrophilic (A) and lipophilic (B) statins. 
 
Table 1.  Clinical pharmacokinetics of HMG-CoA reductase inhibitors (modified from [9-11]). 
Parameter Atorvastatin Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin 
Prodrug No No Yes No No No Yes 
Lipophilicity (Log P) 4.1 3.2 4.3 1.49 - 0.2 - 0.3 4.7 
tmax (h) 2 – 4 0.5 – 1.5 2 – 4 0.5 – 0.8 0.9 – 1.6 3 1.3 – 2.4 
Cmax (ng/ml) 27 – 66 448 10 – 20 26 45 – 55 37 10 – 34 
Absorption (%) 30 98 31 80 35 50 60 – 85 
Hepatic extraction 
(% of absorbed dose) 
>70 68 >70 NA 66 63 78 – 87 
Bioavailability (%) 12 10 – 35 <5 >60 15 – 17 20 <5 
t1/2 (h) 15-30 0.5 – 2.3 2.9 11 1.3 – 2.8 20.8 2 – 3 
Protein binding (%) >98 >99 95 >95% 48 90 95 












Renal excretion (%) 2 6 30 <2 60 10 13 
NA, not available 
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with the results of the large West of Scotland Coronary Pre-
vention Study (WOSCOPS). The WOSCOPS study con-
cluded that the lipid lowering effect of pravastatin could not 
exclusively account for the large benefits evidenced during 
the therapy with the drug, suggesting that other molecular 
mechanisms were associated to statin action [12]. After deep 
investigation, several additional beneficial properties have 
been attributed to statins, such as anti-inflammatory, antioxi-
dant, immunomodulatory, antithrombotic, atherosclerotic 
plaque stabilising and also inhibitory of vascular smooth 
muscle proliferation inhibitory effects [1, 13-16]. Due to 
these so-called pleiotropic effects, it is now considered that 
statins might have a future role in other pathological condi-
tions including: rheumatoid arthritis [17], chronic obstructive 
pulmonary disease [18-20], cancer [21, 22], atrial fibrillation 
[24, 25], Parkinson’s disease [26], Alzheimer’s disease [27-
29], sickle cell disease [30], sepsis [16, 31] and osteoporosis 
[32] (see Table 2). 
However, the extent to which these ‘effects’ occur and 
their clinical relevance is largely debated and many still ar-
gue that statin effects have to be associated only to their cho-
lesterol lowering ability [15, 33]. The mechanisms by which 
these pleiotropic outcomes occur are diverse and have not 
been fully elucidated. Statin-induced hypolipidemic effect is 
mainly related to the inhibition of the HMG-CoA reductase 
responsible for the production of mevalonate, a key interme-
diate in cholesterol biosynthesis. Reduction of hepatic intra-
cellular cholesterol activates sterol regulatory element bind-
ing proteins (SREBPs), causing an increase in the transcrip-
tion of the gene coding for the hepatic low density lipopro-
teins (LDL) receptor. Elevated numbers of LDL receptors 
lead to an increase in the clearance of circulating LDLs, the 
major mechanism by which statins reduce plasma LDL cho-
lesterol. In addition, reduced availability of hepatic free cho-
lesterol and/or cholesteryl esters for incorporation into very 
low density lipoproteins (VLDLs) may reduce the produc-
tion rate of these lipoproteins. Efficacy on triglyceride reduc-
tion parallels LDL cholesterol lowering, as statins inhibit 
hepatic synthesis of apolipoprotein B-100, leading to a re-
duction of the synthesis and secretion of triglyceride rich 
lipoproteins [34]. 
On the other hand, inhibition of mevalonate synthesis 
also causes a decrease in the formation of other important 
isoprenoid intermediates in the cholesterol synthesis path-
way, such as farnesyl phosphate (FPP), geranyl phosphate 
(GPP) and geranylgeranylphosphate (GGPP). These inter-
mediates are involved in a post-translational modification of 
proteins, termed isoprenylation. Isoprenylation affects a 
number of G-proteins: Heme-a, nuclear laminins, small GTP 
binding proteins (GTPases) such as Ras, and Ras-like pro-
teins Rho and Rac. GGPP and FPP are important lipids that, 
when added to intracellular proteins such as Ras, Rho and 
Rac, allow for their attachment to cell membranes. These 
signalling molecules are essential to membrane trafficking, 
transcriptional regulation, cell growth and development and 
switching on and off cellular signalling processes (Fig. 2) 
[34]. The reduction of protein isoprenylation is considered 
the main molecular mechanism underlying most lipid-
lowering-independent effects of statins, collectively termed 
pleiotropic effects [14, 35]. 
 
Fig. (2). Mechanism of action of statins through the inhibition of HMG-CoA reductase. Decrease in isoprenylation of signaling molecules, 
such as Ras, Rho, and Rac, leads to modulation of various signaling pathways. BMP-2: bone morphogenetic protein-2; eNOS: endothelial 
nitric oxide synthase; t-PA: tissue-type plasminogen activator; ET-1: endothelin-1; PAI-1: plasminogen activator inhibitor-1 (modified from 
[14]). 
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In particular, the increased nitric oxide (NO) bioavail-
ability is considered to be a significant factor leading to 
some of the statin pleiotropic actions. Statins increase NO 
via three pathways. statins have been found to activate the 
protein kinase Akt, a signalling molecule, which can directly 
increase NO production. Statins also inhibit Rho pathway, 
which causes the increase of the expression and activity of 
endothelial NO synthase (eNOS) [36]. Lastly, restoration of 
eNOS activity can also be achieved via statin inhibition of 
Rac and the following reduction in in expression of caveolin-
1 that acts as an eNOS inhibitor by forming a complex with 
the enzyme [37]. When NO is formed, it can diffuse into 
adjacent cells and have antithrombotic, anti-inflammatory 
and anti-proliferative effects on endothelial cells leading to 
statin-induced beneficial properties. Furthermore, Rho is 
important in the regulation of pro-inflammatory transcription 
factor in nuclear factor kappa B (NF-B). NF-B plays a 
key role in the transcription of variety of genes involved in 
immune and inflammatory responses. Statins may prevent 
the activation of NF-B, inhibiting the synthesis of inflam-
matory cytokines. Collectively, these mechanisms may ac-
count largely for the anti-inflammatory, anti-atherosclerotic, 
pro-apoptotic and immunomodulatory effects exhibited by 
statins (Table 2). 
However, these effects are concentration-dependent and 
often are only observed at doses higher than the conventional 
cholesterol-lowering ones. At high doses, the risk of adverse 
effects such as myopathy and rhabdomyolysis is signifi-
cantly increased [14]. This has largely limited statins plei-
otropic actions being further investigated. Concurrently, stat-
ins poor bioavailability and toxicity at high concentrations 
mean that new and more efficient dosage forms are needed 
to allow for statin safe administration and to harness their 
new promising therapeutic actions. 
2. BENEFITS OF NANOTECHNOLOGY IN THE 
DRUG DELIVERY OF STATINS 
Numerous nano-sized drug delivery systems have been 
developed to facilitate and optimize the delivery of drugs 
with challenging biopharmaceutical properies [39]. 
Examples of such DDSs are nanocrystals, polymer 
nanoparticles (i.e. nanocapsules and nanospheres), solid 
lipid nanoparticles, liposomes and micelles, which are 
known as nano-sized drug delivery systems or nanocarriers 
(Fig. 3).  
All these formulation approaches differ in their favour-
able characteristics, applicability and drawbacks. However, a 
Table 2.  Proposed therapeutic non-cholesterol lowering role of statins in different disease states. 
Disease State Drug Oral Dose Effect of Statin Reference 
Alzheimer’s Disease Pravastatin 40 mg/day Lowering cholesterol, antithrombotic, anti-1nflammatory effects [28, 29] 





Anti-inflammatory effect, Reduction in serum C-reative protein level [24, 25] 
Cardiac Transplant Pravastatin 20 mg/day 
Reduction in coronary vasculopathy and acute rejection. Direct inhibi-
tion of the induction of MHC-II expression and thus T cell activation. 
[23] 
Chronic Obstructive  
Pulmonary Disease (COPD) 
Statin group NA 










Anti-proliferative, pro-apoptotic and anti-invasive effects in cancer 
cells. Impair angiogenesis. Decrease the ability to metastasize 
[22] 







Reduction in chemokines. Attenuate inflammatory response. Decrease 









Reduction of risk of fractures. Induction of bone formation locally 
through expression of growth factors that promote angiogenesis, bone 
cell differentiation and osteogenesis. 
[32] 
Parkinson’s Disease Statin group NA 
Reduction of risk of Parkinson’s Disease. Anti-inflammatory, 
immunomodulating and neuroprotecting effect. 
[26] 
Rheumatoid arthritis Atorvastatin 40 mg/day 








Protective effect against sepsis through anti-inflammatory and  
immunomodulating effect. 
[31] 
Sickle cell disease Simvastatin 
20-40 
mg/day 
Reduction in coagulation activation, homolysis, inflammation and 
thrombin generation in the vascular pathology of sickle cell disease. 
[30] 
NA, Not Available 
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comprehensive comparison of nano-sized drug delivery sys-
tems is beyond the scope of this review. This article will 
instead focus on nanotechnology-based formulations that 
have been proposed to improve established or enable innova-
tive therapeutic applications of statins. In fact, the re-
formulation of statins with nanocarriers can contribute to 
ameliorate traditional clinical application of statins for cho-
lesterol lowering by enhancing oral bioavailability, reduce 
frequency of administration and limiting drug toxicity. More 
interestingly, statin-containing nanoformulations allow the 
administration of this class of drugs via alternative admini-




Fig. (3). Schematic representation of different nanotechnology 
based drug delivery systems widely used for statins. 
 
2.1. Nanocrystals 
Particle size reduction is one of the most widespread 
techniques to improve the absorption characteristics of 
drugs. Nanocrystals are the first approach that achieved drug 
size reduction to the nanoscale. Nanocrystals can be defined 
as crystals with a size ranging from 1 to 1000 nm. They dif-
fer from other nanosystems as they are composed of 100% 
drug, without polymeric or lipid excipients [45]. Nanocrys-
tals increase the dissolution of drugs by three main mecha-
nisms: increase of specific surface area, enhancement of 
solubility and production of high-energy solid state particles, 
most of them being in an amorphous state. Nanocrystals of 
poorly soluble drugs can be produced either by a building up 
approach (synthesis, self-assembly or precipitation) or by 
top-down technologies based on drug-fragmentation proc-
esses (high pressure homogenization, milling). Critical for 
the generation of stable nanocrystals able to avoid aggrega-
tion and Ostwald ripening is the addition to the nanoparticle 
dispersion of excipients able to provide steric and/or ionic 
stabilization to control particle size and size distribution [46, 
47]. 
Statins have been employed in the form of nanocrystals 
to improve their solubility and dissolution properties. Athul 
and co-workers prepared a promising simvastatin nanosus-
pension by high-pressure homogenization technique having 
good stability, enhanced dissolution rate, solubility and per-
meability compared to crude drug. These properties in-
creased the drug oral bioavailability and its in vivo absorp-
tion rate. In vitro drug release data showed a maximum cu-
mulative percentage of dissolved drug of 98.7% within 1 
hour, whereas 45.9% only was reached by the crude drug 
[48]. 
Another group has developed nanocrystals of atorvastatin 
with the same approach, showing complete drug dissolution 
within 30 minutes from crystals with a dv50 of 0.241 m [49]. 
Simvastatin nanocrystals (300 nm) obtained by nanoprecipi-
tation in presence of surface stabilizers such as polyvinylpyr-
rolidone K-30 and sodium laurylsulphate, showed a similar 
increase in dissolution rates in vitro in comparison with 
commercial crystalline drug [50]. In a recent study, simvas-
tatin nanocrystals prepared by sonoprecipitation method in 
presence of Pluronic F68 (360 nm) showed increased disso-
lution rate (4 fold), faster absorption (tmax reduced to 1.99 h 
from 2.88 h) and enhanced bioavailability (1.5 times in-
crease) in comparison to crude simvastatin after oral admini-
stration to rats [51]. 
Amorphous atorvastatin calcium nanosystems were pre-
pared using a supercritical antisolvent (SAS) process  
(Fig. 4). Mean particle size of the spherical particles obtained 
ranged from 153 and 863 nm and was strongly influenced by 
drug concentration and CO2/drug solution feeding rate. In-
trinsic dissolution rate, solubility and oral bioavailability in 
rats were significantly enhanced when compared to the un-
processed crystalline raw material [52]. 
Anwar and colleagues developed an unconventional 
nanocrystal system of atorvastatin-chitosan conjugate 
[53]. The nanocrystal drug delivery system was obtained 
from the lyophilised drug-polymer conjugate, which after 
high pressure homogenization formed a colloidal suspen-
sion with an average size of 215 nm. When administered 
orally to rats, this nano-sized drug-chitosan conjugate was 
shown to improve the pharmacokinetic properties of 
atorvastatin, increasing its plasma half-life, Cmax and AUC 
(5 fold) in comparison with unprocessed atorvastatin. The 
results were attributed to the conjugate increased solubil-
ity (100 times) and faster dissolution rate, while the mu-
coadhesive properties of chitosan allowed increased reten-
tion time in the gut. The enhanced bioavailability was 
attributed not only to particle nanosize, but also to a de-
creased metabolism of the drug by cytochrome P450 en-
zyme [53]. Such a formulation could be used to lower 
traditional dosing of statins and reduce the frequency of 
side effects. Additionally, this nano-formulation may also 
be promising for administration by other routes, where the 
mucoadhesive and permeation enhancing properties of 
chitosan are deemed favourable. 
2.2. Nanoparticles 
Nanoparticles in pharmaceutics are defined as solid col-
loidal particles up to 1000 nm in the form of nanospheres or 
nanocapsules. Nanospheres have a matrix type structure, in 
which the drug may be homogeneously dispersed throughout 
the core or adsorbed on the particle’s surface. In contrast, 
nanocapsules are typical reservoir systems in which a core 
confining the drug is coated by an external shell controlling 
drug release [54-56]. Nanoparticle formulations appear to 
offer unique characteristics for the future drug delivery of 
statins. Nanoparticles are able to protect drugs from degrada-
Expanding the Therapeutic Potential of Statins Current Topics in Medicinal Chemistry, 2014, Vol. 14, No. 9    1187 
 
Fig. (4). SEM images of unprocessed atorvastatin calcium (a) and processed atorvastatin calcium precipitated by the SAS process (b) (modi-
fied from [52]). 
 
tion and provide tailored release properties. Nanoparticle 
behaviour in the biological environment, stability and biodis-
tribution will depend on their composition, surface proper-
ties, morphology and size. In particular, particles above one 
hundred nanometers provide high drug payload, but are more 
susceptible to interaction with biological matrices, such as 
mucus or blood proteins, and to scavenging by macrophages 
compared to smaller particles (<50 nm) [57]. 
As discussed, the short half-life and low bioavailability 
are the major noticeable drawbacks of the therapy with stat-
ins. To overcome these drawbacks researchers suggested the 
development of nanoparticulate formulations. Many methods 
have been employed to prepare/formulate nanoparticles with 
optimal particle size for the specific administration, reduced 
uptake by cells of the reticuloendothelial system (RES) when 
administered parenterally and/or preferential distribution to 
specific cells or tissues in order to obtain targeted drug de-
livery [44]. In particular, poly(lactic-co-glycolic acid) 
(PLGA) copolymers have been extensively used in develop-
ing statin-loaded nanoparticles. For example, Soni and co-
authors have focused on improving the absorption of statins 
in the gastrointestinal tract using simvastatin PLGA nanopar-
ticles [58]. These nanoparticles, administered per os as a 
suspension, showed a significant reduction in cholesterol 
serum lipid levels (as opposed to non encapsulated simvas-
tatin), producing a 5 fold decrease in total cholesterol and 2.8 
fold decrease in triglyceride levels. This was mainly attrib-
uted to the increased apparent solubility in aqueous media of 
simvastatin in consequence of its being loaded into nanopar-
ticles. Interestingly, it was shown that PLGA nanoparticles 
had a biphasic release pattern. In vitro drug release from the 
nanoparticles showed an initial burst release of 40% in the 
first 4 hours, which was considered beneficial to improve 
drug absorption, followed by a phase of slow release of the 
drug [58]. In another approach, the water soluble statin flu-
vastatin was encapsulated into a novel fast degrading polyes-
ter, poly(propylene succinate) (PPSu), in view of a once-a-
day formulation. Fluvastantin loaded nanoparticles were 
produced by w/o/w emulsification method using polymers 
various molecular weight and showed particles size between 
150 and 1800 nm. After a burst release in the first hour, ex-
tended release profiles could be obtained only with high mo-
lecular weight PPSu. Such a drug delivery system appears 
promising to lower fluvastatin oral daily dosing and reduce 
adverse drug reactions associated with high dose statin regi-
mens [59]. 
Cubic nanoparticles obtained from glyceryl monooleate 
and poloxamer 407 have been proposed as a potential drug 
delivery system to enhance bioavailability of simvastatin. 
Cubic nanoparticles obtained by fragmentation of the bulk 
cubic phase gel formed by the components showed particle 
sizes in the 100-150 nm range and a simvastation loading up 
to 5%. Despite simvastatin was not released significantly by 
the nanoparticles neither in simulated gastric fluid nor in 
fasted-state simulated intestinal fluid, pharmacokinetics stud-
ies carried out in dogs showed an increase in oral bioavail-
ability of over 2.4-fold when simvastatin was administered 
as cubic nanoparticles compared to micronized crystal pow-
der, as a result of a facilitated and prolonged absorption of 
the drug from the nanoformulation [60]. 
Lovastatin has been formulated in PLGA nanoparticles 
with the aim of enhancing bone repair when administered 
locally. Nanoparticles prepared by emulsification/solvent 
evaporation method showed particle size ranging from 200 
to 400 nm increasing on lovastatin encapsulation. Release of 
lovastatin was found to be almost complete (97%) over 7 
days. In vivo studies evidenced that 1 mg lovastatin-PLGA 
nanoparticles were the most efficient treatment in stimulat-
ing faster bone regeneration when locally administered to 
rats with surgically caused bony defects in comparison to 
control animals [61]. 
Pitavastatin PLGA nanoparticles have been proposed as 
an effective treatment for pulmonary artery hypertension. 
Pitavastatin was found to be the most potent among statins in 
mitigating endothelial injury, inhibiting vascular remodelling 
and inflammation. In a rat model of monocrotaline-induced 
pulmonary artery hypertension, a pitavastatin nanoparticles 
suspension administered via intratracheal instillation induced 
reduction of the hypertension and improved survival rate 
compared to pitavastatin alone administered in the same way 
or systemically. The beneficial effects of pitavastatin-
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nanoparticles were attributed to their accumulation in alveo-
lar macrophages and small pulmonary arteries up to 14 days 
after intratracheal instillation [62]. 
The use of statins has also been suggested for the treat-
ment of many neurological disorders. Statins can provide 
neuroprotective effects via various mechanisms such as cho-
lesterol lowering, reduction in reactive oxygen species, en-
hancement of cerebral blood flow and suppression of -
amyloid production and serum apolipoprotein E levels. 
Moreover, statin neuroprotective effects extend to anti-
thrombotic effects, anti-inflammatory responses, modifica-
tion of cognition related receptors, reduction of matrix met-
alloproteases and augmentation of endothelial nitric oxide 
synthase (eNOS). Therefore, it is expected that statins could 
provide benefit in diseases such as Alzheimer’s disease, 
Parkinson’s disease, cerebral ischemic stoke, vascular de-
mentia and other cerebrovascular diseases which have been 
linked to high cholesterol as well as to prothrombotic and 
inflammatory states [63]. However, the passage of drugs 
across the blood brain barrier (BBB) has always represented 
a challenging physiological hurdle to the distribution of 
drugs to the central nervous system, the rate-limiting step 
being the presence of endothelial cells provided with tight 
junctions and efflux proteins, hindering the crossing to most 
drug molecules. Recent studies have shown how polysorbate 
80-coated nanoparticles may constitute an interesting ap-
proach for improving BBB permeation. The mechanism by 
which this occurs is still not fully understood. However, it is 
known that coating with polysorbate 80 allows nanoparticles 
to accumulate at the brain micro-vessel endothelial cell sur-
face [64, 65]. Simsek and collaborators explored this formu-
lation approach to load atorvastatin in PLGA nanoparticles 
coated with poly(ethylene glycol) (PEG) and polysorbate 80 
and to compare them to nanoparticles without polysorbate 80 
on their surface. Both nanoparticles were labelled with Nile 
red fluorescent marker and tested on in vitro vascular endo-
thelial cell cultures and in vivo in rat model. Interestingly, in 
vitro results indicated no significant effect of polysorbate 80 
coating on nanoparticle uptake. However, in vivo results 
found that, although the imaging techniques were only quali-
tative, polysorbate 80 nanoparticles reached a higher fluores-
cence in the brain at 1 hour after administration over control 
nanoparticles, which may indicate an increase in polysorbate 
80 nanoparticle CNS penetration [66]. This new formulation 
approach may be promising for a number of disorders such 
as Alzheimer’s disease, stroke, Parkinson’s disease and mul-
tiple sclerosis, for which a the beneficial effect of statins has 
been postulated, but not demonstrated via conventional statin 
administration. 
More recently nanoparticles have been designed to target 
specific cells, organs and tissues. Nanoparticles are able to 
target cells through conjugation to a number of ligands able 
to bind to receptors and other membrane proteins typically 
expressed by a specific organ or cell population [55]. By 
localising the effect of statins to a particular area, some of 
the their pleiotropic effects may be amplified. For example, 
it has been postulated that a role exists for statins as potential 
new therapeutic agents able to promote neovascularisation in 
patients with ischemia and coronary artery disease. The 
mechanism by which this occurs has not been fully eluci-
dated yet, but it has been suggested that statins increase en-
dothelial progenitor cells (EPC) and promote their differen-
tiation into mature endothelial cells by activating AKT pro-
tein kinase [67]. These effects have been observed in several 
studies at high doses of statins, but significant concerns were 
raised regarding potential adverse reactions [68]. Kubo and 
co-workers have tried to overcome this issue by developing 
biodegradable PLGA nanoparticles able to target the vascu-
lar endothelium [69]. Intramuscular injection of biodegrad-
able pitavastatin loaded PLGA nanoparticles resulted in cell-
selective delivery into capillary and arteriolar endothelial 
cells. Pitavastatin-loaded PLGA nanoparticles were shown to 
increase angiogenic activity and promote neovascularisation 
at doses that were 100 times as lower than those obtained by 
cumulative oral dosing. In addition, when nanoparticles con-
taining pitavastatin were delivered to vascular endothelial 
cells, they induced increased neovascularization and im-
proved tissue perfusion in a murine model of hind limb 
ischemia, indicating that this novel cell-selective delivery 
system is feasible for therapeutic neovascularization. It was 
noticed that nanoparticles were localised in the vascular en-
dothelium and none detected in other organs such as the 
liver, kidney, or heart at any time point up to 14 days. This 
selectivity was attributed to an increased endocytosis of 
nanoparticles by the vascular endothelium cells. Further-
more, pitavastatin formulated in nanoparticles showed no 
effect on serum lipid levels in rat ischemic models. The ab-
sence of effects on lipid levels strongly suggests a different 
mechanism by which statins act, not related to the classic 
cholesterol-lowering effects. Although the authors of this 
study did not see an increase in EPC as they hypothesised, a 
rise in phosphorylated endothelial nitric oxide synthase 
(eNOS) and protein kinase AKT was observed which might 
account for the observed therapeutic effects [69]. 
A targeting approach has also been proposed to increase 
the potential for statins to be used in the stabilisation of athe-
rosclerotic plaques. It has been hypothesised that statins role 
in plaque stabilisation may occur for a number of reasons 
including the up regulation of eNOS, a pathophysiological 
marker which is down regulated in a prothrombic or proat-
herogenic state. Moreover, statins have the ability to reduce 
matrix metalloproteinase secretion in macrophages, physio-
logical proteins which result in plaque matrix degradation 
and consequent plaque vulnerability. Statins have also been 
shown to inhibit macrophage activity and proliferation add-
ing to their effects on plaque stabilisation [70]. Broz and 
colleagues have tried to exploit the beneficial effect of stat-
ins by targeting activated macrophages present in atheroscle-
rotic plaques. By creating a selective targeted system, the 
hope is to avoid local tissue damage and serious side effects 
such as rhabdomyolysis. Pravastatin-loaded targeted 
nanoparticles were obtained by functionalising the polymer, 
i.e. poly (dimethylsiloxane) (PDMS) with two poly(2-
methyloxazoline) (PMOXA) side chains, with an oligonu-
cleotide (polyG) through a biotin/streptavidin functionaliza-
tion approach [71]. It was shown on cell cultures that func-
tionalised nanoparticles enabled the pravastatin to penetrate 
into macrophages with controlled intracellular release only 
into desired cell lines with no toxic effect on smooth muscle 
cells viability. Interestingly, it was shown that pravastatin 
alone had no effect on macrophages being too hydrophilic to 
get into macrophages. However, owing to the targeted 
nanoparticle formulation, no such limitation was evident, 
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allowing pravastatin intracellular delivery [71]. Further in-
vestigation with a targeted nanoparticle therapy in vivo is 
needed to establish any potential therapeutic benefit of stat-
ins. Nanoparticles may provide a large benefit to patients at 
high risk of plaque rupture allowing statins to reach and ex-
ert inhibitory effects on macrophages safely for patients even 
at high concentrations. 
2.3. Solid Lipid Nanoparticles 
Solid lipid nanoparticles (SLNs) provide a promising ap-
proach for the delivery of poorly water soluble compounds 
such as statins. These are typically spherical solid nanoparti-
cles with a drug-containing solid lipid core stabilised with 
surfactants or stabilisers, with sufficient physical stability for 
long time storage. The preparation process generally in-
volves emulsification by homogenisation at high temperature 
of the molten solid lipid containing the drug. SLNs provide 
controlled release of drugs and have been shown to improve 
oral bioavailability of lipophilic drugs. Alternatively to po-
lymeric nanoparticles, solid lipid nanoparticles are also con-
sidered to have appealing characteristics as nanocarriers. In 
fact, solid lipid nanocapsules and nanostructured lipid carri-
ers offer additional advantages such as enhanced biocom-
patibility, lower toxicity, excellent biodegradability, in-
creased drug encapsulation and stability [72]. Hence, SLNs 
are a promising sustained-release and drug-targeting system 
for statins. Furthermore, solid lipid nanoparticles adminis-
tered orally may be able to bypass first pass metabolism by 
taking advantage of intestinal lymphatic transport [44]. A 
complete optimisation study of simvastatin loaded lipid 
nanoparticles has been conducted by Shah and Pathak [73]. 
It was found that second generation lipid carriers, called 
nanostructured lipid carriers (NCLs), composed of mixtures 
of solid and liquid lipids, were superior in improving 
bioavailability than conventional SLNs produced using only 
solid lipids. SLNs presented two main disadvantages in 
comparison with NLCs. The first was a reduced drug loading 
capacity and the second a progressive drug leakage during 
storage [73]. The pharmacokinetic parameters after oral 
administration in mice revealed a 4.8 fold increase in 
bioavailability as compared to simvastatin suspension and a 
2.3 fold increase as compared to SLNs. A biodistribution 
study revealed preferential accumulation of NLCs in the 
liver and this was considered advantageous as the liver is the 
target organ for simvastatin [74]. In a similar approach, the 
bioavailability of lovastatin could be improved by adminis-
tering it orally into solid lipid nanoparticles. Lovastatin 
loaded SLNs were developed using triglycerides by hot ho-
mogenization followed by ultrasonication, obtaining parti-
cles with a mean size range from 60 to 119 nm and a nega-
tive zeta potential. In addition, the report showed enhanced 
oral bioavailability in comparison with orally dosed lovas-
tatin suspension. After intra-duodenal administration in rats 
relative bioavailability of lovastatin and lovastatin hydroxya-
cid of SLN formulation were increased by 173% and 324%, 
respectively, compared with the reference lovastatin suspen-
sion [75]. Therefore, formulating statins into NLCs may of-
fer substantial benefit to increase their oral bioavailability. 
However, this is not the only proposed use for statins 
formulated in lipid nanocarriers. Several studies have be-
come available demonstrating statin ability to suppress 
growth and/or induce apoptosis of cancer cells. It has there-
fore been suggested that combining statins with other anti-
proliferative agents and/or formulating them into nanoparti-
cles could enhance this effect. Nanoparticles are particularly 
beneficial in targeting tumours. Tumour vasculature, unlike 
the one in normal tissues, presents gaps as large as 600-800 
nm between endothelial cells. As a consequence of tumour 
leaky and defective vessels and poor lymphatic drainage, 
nanoparticles are able to passively accumulate in the tu-
mours. However, this phenomenon called enhanced perme-
ability and retention effect, can be exploited by nanoparticles 
having sufficiently small particle size (10-100 nm) to both 
avoid the capture of liver and spleen macrophages and take 
advantage of the defective architecture of tumour blood cap-
illaries [76]. To investigate this concept, simvastatin and 
tocotrienols were combined in lipid nanocarriers. To-
cotrienols are a vitamin E family compounds found in palm 
oil. Previous studies showed that low dose statins and to-
cotrienols had no effect on cancer cells individually, whereas 
their combination significantly inhibited tumour cell growth. 
Collectively, simvastatin-tocotrienol co-encapsulated in lipid 
nanoparticles were shown to act synergistically increasing 
the intrinsic apoptotic effect compared to the two drugs sepa-
rately [77]. These studies highlight the possibility of using 
nanoparticles for formulating multiple drugs into one drug 
delivery system, demonstrating their potential in enhancing 
and facilitating complex therapies. 
2.4. Liposomes 
Since they were first developed by Alexander Bangham 
in the 1960 as an analytical tool to study bio-membrane 
dynamics [78], the potential of these closed phospholipid 
bilayer vescicles as a drug delivery carrier promptly 
appeared with the first in vivo experiments. Liposomes are 
attractive drug carriers due to their tunable physical charac-
teristics, good encapsulation efficiency of both hydrophilic 
or hydrophobic drugs, ability to protect drugs from degrada-
tion and the possibility of being functionalised with moieties 
to create targeted nanosystems [79, 80]. Due to these favour-
able characteristics, along with the fact that they are pro-
duced with highly biocompatible lipids, liposomes have be-
come the first approved nano-sized drug delivery systems 
[81]. Despite chemical and physical stability of liposomes 
upon long-term storage as aqueous dispersion may still be 
considered a critical issue, with aggregation, vesicle fusion, 
drug leakage and phospholipids degradation being their most 
relevant drawbacks, up to date liposomes remain the most 
successful nanocarriers in clinical use [82, 83]. Therefore, it 
seems reasonable to consider liposomes a formulation ap-
proach to improve and extend the therapeutic use of statins. 
Currently developed statin liposomal formulations have 
mostly explored the anti-inflammatory effects of statins. As 
previously described, it is hypothesised that statins anti-
inflammatory properties are due their inhibition of the me-
valonate pathway. Similarly to how statins inhibit the pro-
duction of squalene and thus cholesterol, statins also inhibit 
the prenylation of Ras, Rho and Rac. As a consequence, stat-
ins have been shown to have anti-inflammatory properties 
such as augmentation of eNOS activity and inhibition of 
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cytokine production including MPC-1, IL-8, IL-1B and TNF 
alpha [13]. This makes statins interesting as drug therapies 
for inflammatory conditions related to damaged myocar-
dium, percutaneous coronary intervention and tumours. 
Afergan has investigated the anti-inflammatory proper-
ties of statin loaded liposomes. It has been shown that in-
flammation associated with percutaneous coronary interven-
tion is one of the most significant predictors of poor thera-
peutic outcome with this surgery. The damaging inflamma-
tory processes involve monocyte adhesion, macrophage ac-
cumulation and smooth muscle cell proliferation. Simvas-
tatin liposomes administered intravenously to rats were 
found to be 1.5-2 times more potent in suppressing mono-
cytes and macrophages activity than free circulating drug 
[84]. It is hoped that use of simvastatin liposomes may act as 
anti-inflammatory agents in percutaneous coronary interven-
tion, the final goal being to decrease restenosis rates.  
In another study, the effect of pravastatin-loaded 
liposomes was studied on the growth rate of three different 
tumour-related cells types, i.e., tumour cells, endothelial 
cells and macrophages. To do this, pravastatin was formu-
lated into long circulating liposomes hoping for reaching 
high local drug concentrations in the tumor. In vitro experi-
ments showed that liposomal pravastatin exerted the most 
significant effect on macrophage viability. For in vivo ex-
periments, melanoma cells bearing mice were given intrave-
nous injections of pravastatin or liposomal pravastatin. 
Liposomal pravastatin was shown to significantly slow down 
tumour growth by 70%, whereas pravastatin therapy alone 
had no effect. Interestingly, liposomal pravastatin was shown 
to effectively inhibit the several proteins involved in in-
flammation and angiogenesis compared to free circulating 
drug. When compared 48 hours post administration, drug 
loaded liposomes were shown to be present in the blood and 
other tissues, while the free drug was only found in the liver. 
Serum cholesterol levels were unaffected by pravastatin-
loaded liposome therapy (Fig. 5) [85]. This demonstrates the 
importance of the nano-formulation in controlling the tissue 
distribution of statins, thus promoting pleiotropic effects. 
Targeted liposomal formulations have been developed to 
selectively deliver pravastatin to damaged myocardium 
where the statin can best exert its anti-inflammatory proper-
ties. Pravastatin was encapsulated in liposomes conjugated to 
N-acetylglucosamine, which has been shown to bind to cell 
surface lectins on cardiomyocytes. The hydrophilic nature of 
pravastatin normally makes intracellular uptake of pravas-
tatin into cardiomyocytes difficult, unlike other lipophilic 
statins. It was shown that by encapsulating pravastatin into a 
N-acetylglucosamine conjugated liposome, pravastatin was 
successfully endocytosed into cardiomyocytes in in vitro 
experiments. This resulted in increased nitric oxide synthase 
expression and thus NO production. Similar results were not 
seen in non-targeted pravastatin liposomes [86]. A targeted 
N-acetyl glucosamine conjugated liposomal system encapsu-
lated with cardio-protective agents such as statins as well as 
other anti-inflammatory agents, appears as promising drug 
delivery system to specifically target damaged myocardial 
cells. Further investigation is now needed to determine the 
level of expression of lectin receptors in different body re-
gions to determine how specific this targeting approach 
might be in vivo. 
 
Fig. (5). Blood and tissue levels of pravastatin in melanoma-bearing 
mice receiving free (PRV) or liposomal pravastatin (LCL-PRV) 
(reproduced with permission from [85]). 
2.5. Micelles 
Micelles are successfully used as pharmaceutical carriers 
for poorly water soluble drugs for their small size, specific 
cell targeting capacity, minimized toxicity, stability in GI 
tract, good biocompatibility and solubilizing properties. Mi-
celles are self-assembled nanosized colloidal particles (5 to 
100 nm) with a hydrophobic core and a hydrophilic shell, 
which form spontaneously under certain concentrations and 
temperatures from amphiphilic or surface active agents. The 
hydrophobic core of micelles is capable of carrying poorly 
water-soluble drugs with high loading capacity (i.e., 5–25% 
weight), presently many of these drug-loaded micelles are at 
different stages of preclinical and clinical trials as useful 
tools to deliver drugs orally and enhance their bioavailability 
[87, 88]. Statins have been considered excellent candidates 
for encapsulation into micelles due to their mainly hydro-
phobic characteristics. As already discussed, statins show 
anticancer effects related to their anti-inflammatory and pro-
apoptotic properties. These anticancer properties have been 
investigated using copolymers of stearyl chitosan (SC) and 
sulphated stearyl chitosan, which could self-assemble to 
form polymeric micelles containing atorvastatin. In vitro 
release studies showed that encapsulated atorvastatin mi-
celles provide a sustained release profile, likely due to mi-
celles forming a physical barrier around the drug. Cytotoxic 
studies were also conducted on human breast adenocarci-
noma cell line (MCF 7) and human colon carcinoma cell line 
(HCT 116). Atorvastatin-loaded micelles showed enhanced 
cytotoxicity in both cell lines compared to free drug. It was 
suggested that chitosan facilitated adhesion to cell mem-
branes allowing increased intracellular uptake of micelles. In 
particular, it was hypothesised that uptake occurred through 
the accumulation and endocytosis of micelles at few cationic 
sites present on the cell surface of tumours [89]. Simvastatin 
loaded poly(ethylene glycol)-poly (caprolactone) micelles 
were developed by Liu to optimise simvastatin delivery for 
bone regeneration. The in vitro release behaviour of simvas-
tatin from the 80 nm micelles was prolonged. It was shown 
that simvastatin-loaded micelles caused an effective inhibi-
tion of the osteoblast early proliferation, stimulation of os-
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teoblast differentiation and mineralization, and increased 
expression of the bone morphogenic protein 2 [90]. 
2.6. Nano-Enabled Drug Delivery Systems 
Nanotechnology is further expanding, continually pro-
ducing innovative drug delivery devices. Nano-enabled de-
vices are drug delivery systems, generally novel implantable 
systems, which are macroscopic in size with some nanomet-
ric features crucial for their specific therapeutic action. These 
drug delivery devices combine the advantages of nanotech-
nology, such as increased drug availability and decreased 
side effects, with an extended release profile to aid compli-
ance for patients and increase therapeutic efficacy. The ex-
tended release properties of these nano-enabled devices are 
particularity useful for chronic disease states [91]. A nano-
channel drug delivery device incorporating atorvastatin and 
trans-resveratrol has been proposed to promote cardioprotec-
tion. Trans-resveratrol has has been proven effective in re-
ducing oxidative stress and able to increase nitric oxide syn-
thase expression in cardiomyocytes. Combining trans-
resveratrol with atorvastatin creates a synergistic effect, 
which, when delivered locally to tissue, may help treat or 
prevent the progression of heart disease. The implantable 
drug delivery system is composed of a nano-fluidic mem-
brane consisting of thousands of tightly packed nanochan-
nels. The nanochannels achieve an extended constant release 
of drug through carefully geometrically designed slits. Test-
ing of the drug delivery device was completed in vitro and 
showed zero-order release kinetics for more than one month. 
The implantable nano-enabled device displayed good endo-
thelial biocompatibility [92]. In addition, the ability to finely 
tailor the number of nanochannels present offers a promising 
tool for personalised patient treatment. 
Similarly, Tsukie and co-authors have investigated the 
delivery of statin drugs by means of innovative devices [93]. 
The authors incorporated pitavastatin nanoparticles into 
coronary artery stents in order to exploit statins vasoprotec-
tive properties. Current drug eluting stents incorporate si-
rolimus and paclitaxel. Concerns have been expressed over 
the safety of these devices as they are suspected to impair re-
endorevascularisation and cause inflammation. Pitavastatin 
nanoparticle drug eluting stents were tested in pig coronary 
artery models to investigate their effectiveness in compari-
son to the current accepted therapy. Pitavastatin nanoparti-
cles consisted of PLGA with surface modification of chito-
san and were loaded onto stents by cationic electrodeposition 
coating technology. Pitavastatin nanoparticle eluting stents 
were shown to be as effective as sirolimus-eluting stents. In 
comparison, intracoronary administration of pitavastatin 
nanoparticles was shown ineffective, exhibiting the impor-
tance of the incorporation into an implantable local delivery 
device. Most significantly, pitavastatin therapy did not pro-
duce the delayed healing effects evidenced in sirolimus-
eluting stents [93]. Local administration of pitavastatin 
nanoparticles may provide consistent and effective treatment 
of coronary artery disease, for patient at risk of in-stent 
thrombosis. 
CONCLUSION 
As Dr. Ruth Duncan, Chair of the European Science 
Foundation, defined it, nanomedicine is “the science and 
technology of diagnosing, treating and preventing disease 
and traumatic injury, of relieving pain, and of preserving and 
improving human health, using molecular tools and molecu-
lar knowledge of the human body” [94]. To achieve this 
goal, nanomedicines must be supplied, i.e. dosage forms, 
comprising an active drug plus excipients, substantially de-
riving from a dramatic size reduction of more conventional 
dosage forms. 
Pharmaceutical nanotechnology offers a range of benefits 
to the therapeutic delivery of statins, the most significant 
being the increase in statin oral bioavailability. This allows 
statins to be administered at lower doses, reducing the risk of 
side effects such as rhabdomyolysis. The increased bioavail-
ability of statins occurs mainly through two mechanisms 
including the increased dissolution of statins in the gastroin-
testinal tract and the bypass of first pass metabolism, a 
physiological barrier that significantly prevents statins from 
reaching significant systemic concentrations. Most impor-
tantly, the increased bioavailability achieved by statin-loaded 
nanocarriers allows statins pleiotropic effects to be exploited. 
Through nanocarriers, statins have the potential to exert anti-
inflammatory, antioxidant, immunomodulatory and anti-
thrombotic effects. In particular, nanotechnology targeted 
systems offer the highest potential for triggering these effects 
of statins, allowing them to be delivered locally to the site of 
action in significant concentrations. In an attempt to compare 
the nanotechnological approaches here reviewed, it is clear 
that the preference for one nanocarrier or another should be 
driven by the therapeutic need first and then also by techno-
logical considerations. The therapeutic need and goal deter-
mine the amount of drug to be administered via a certain 
route. Consideration should be paid to the fact that drug 
loading capacity changes among the available nanosytems. 
In the typical use of statins for lowering cholesterol blood 
levels, as oral administration is performed, improved disso-
lution is the goal to improve bioavailability and reduce the 
doses. Nanocrystals, micelles and lipid-based nanoparticles 
(SLNs, NLCs) should be considered as first choice for their 
positive effect on drug solubilisation in the gastrointestinal 
tract due to the reduced particle size of the pure drug or a 
“formulation effect” exerted by lipid excipients. Liposomes 
as well as polymeric nanoparticles should be considered for 
use via administration routes other than oral and, in particu-
lar, when the therapeutic goal requires sustained release, site-
specific distribution and specific targeting properties of the 
carrier. Then, in front of the choice between liposomes and 
polymeric nanoparticles, stability and biocompatibility of the 
formulation should be taken into account as well as the drug 
release characteristics of each nanocarrier. As far as pro-
longed release of the drug at site of action is concerned, for 
instance after direct injection of the carrier in the tissue, po-
lymeric nanoparticles may represent a golden standard to 
obtain a depot effect. Finally, as other potential applications 
of statins include the treatment of neurological disorders 
such as Alzheimer’s disease, solid lipid nanoparticles so far 
appear as the most interesting nanocarrier to target the cen-
tral nervous system. 
As last reflection, when the actual nanoparticle-based 
drug delivery system has been manufactured, product devel-
opment may not be over yet. Indeed, the nanocarrier eventu-
ally has to become a finished medicinal product to be used 
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safely and effectively in clinical practice. Beside any consid-
eration on the large-scale production of these nanosystems, 
which could be not always straightforward, it cannot be ex-
cluded that for administration purposes, stability issues or 
patient convenience and compliance, the nanocarrier should 
be further transformed into a transitorily larger dosage form. 
Suitable technologies are needed to achieve this transforma-
tion that should only temporarily “mask” the nanoparticles 
within a bigger structure. For instance, an example of how 
this can be done was described by Cagnani et al. [95] who 
realised a powder for nasal delivery of drug-loaded nanopar-
ticles: a spray drying process (in the presence of a filler) 
transformed the nanoparticles into microparticles, which 
were then agglomerated by tumbling to form coarse soft 
globules. After insufflation, these agglomerates broke down 
into smaller fragments of aggregated microparticles, which 
released intact, upon disintegration in physiological fluids, 
the original nanocarrier. In this way a solid finished product 
containing the nanocarrier can be proposed as components of 
classical dosage forms to suit different routes of administra-
tion, therapies and patients [96]. 
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